Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder

Allergan

Status: Completed

Conditions: Urinary Bladder, Overactive

Treatments: Drug: onabotulinumtoxinA

Study type: Observational

Funder types: Industry

Identifiers

NCT02557971

GMA-US-OAB-0403

Details and patient eligibility

About

This study is a retrospective chart review of patients treated with BOTOX® for idiopathic Overactive Bladder (OAB) as standard of care in clinical practice. The study will determine the rate of post procedural urinary retention requiring catheterization and identify factors that may predict urinary retention.

Enrollment: 315 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

-Patients treated with BOTOX® for Overactive Bladder.

Exclusion criteria

• Received botulinum toxin formulations other than BOTOX® in the bladder.
• Had symptoms of OAB associated with a neurological condition.
• Had a history of chronic urinary retention treated with Clean Intermittent Catheterization (CIC) or indwelling catheter.

Trial design

315 participants in 1 patient group

BOTOX®

Description:

Patients with idiopathic overactive bladder (OAB) treated with onabotulinumtoxinA (BOTOX®) injections into the bladder as standard of care in clinical practice. No intervention was administered in this study.

Treatment:

Drug: onabotulinumtoxinA